How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 11 Jul | 18 Jul | 25 Jul | 24 Aug | 28 Aug | 04 Sep | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 52.7 | 54.5 | 54.5 | 55.0 | 55.0 | 55.0 | +2.3 |
| Healthcare | 32.6 | 32.7 | 32.7 | 36.7 | 36.7 | 36.7 | +4.1 |
| Chemicals | 7.6 | 8.0 | 8.0 | 5.2 | 5.2 | 5.2 | -2.4 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 10.69% | 7 | 8 | 7 | 8 | 5 | — | +1.5% |
| DIVISLAB | Pharma | 9.47% | 9 | 8 | 1 | 4 | 1 | — | +38.4% |
| TORNTPHARM | Pharma | 6.89% | 7 | 8 | 5 | 4 | 1 | — | +7.0% |
| APOLLOHOSP | Healthcare | 6.62% | 9 | 5 | 5 | 2 | 2 | — | +0.4% |
| NEULANDLAB | Healthcare | 5.57% | 8 | 10 | 7 | 4 | 1 | — | +30.4% |
| NAVINFLUOR | Chemicals | 5.20% | 9 | 10 | 4 | 8 | 1 | Leader | +20.9% |
| AUROPHARMA | Pharma | 5.02% | 8 | 3 | 10 | 6 | 7 | — | +9.9% |
| ZYDUSLIFE | Pharma | 4.90% | 9 | 10 | 10 | 2 | 8 | — | +1.9% |
| ASTERDM | Healthcare | 4.67% | 6 | 2 | 9 | 4 | 2 | — | -0.6% |
| FORTIS | Healthcare | 4.16% | 4 | 8 | 5 | 5 | 6 | — | -12.4% |
| GLAND | Pharma | 3.60% | 10 | 7 | 5 | 4 | 4 | Leader | +27.9% |
| MEDANTA | Healthcare | 3.20% | 8 | 9 | 5 | 4 | 2 | — | +13.1% |
| MANKIND | Pharma | 3.12% | 4 | 8 | 9 | 3 | 5 | — | -6.1% |
| IPCALAB | Pharma | 2.97% | 9 | 5 | 1 | 3 | 4 | — | +14.3% |
| ARTEMISMED | Healthcare | 2.86% | 10 | 9 | 5 | 2 | 3 | — | +28.8% |
| MAXHEALTH | Healthcare | 2.84% | 1 | 9 | 6 | 5 | 6 | — | -6.0% |
| METROPOLIS | Pharma | 2.82% | 8 | 9 | 6 | 7 | 1 | — | +4.7% |
| BIOCON | Pharma | 2.77% | 4 | 1 | 10 | 2 | 7 | — | -8.8% |
| GLENMARK | Pharma | 2.74% | 10 | 9 | 9 | 4 | 3 | — | +8.2% |
| ONESOURCE | Healthcare | 2.49% | 3 | 1 | 6 | 7 | 8 | — | -15.1% |
| COHANCE | Healthcare | 2.37% | 4 | 5 | 6 | 3 | 5 | — | +1.5% |
| AGARWALEYE | Healthcare | 1.94% | 8 | 5 | 8 | 1 | 3 | — | +10.3% |
Performance · 3.1y
Over the last 3.1 years ₹100 in the fund grew to ₹182 (+82%), vs ₹136 for Nifty 500 (+36%) and ₹120 for Nifty 50 (+20%). Its relative-strength line ended at 151 vs Nifty 50 and 134 vs Nifty 500 — above 100, sustained outperformance.